Publications by authors named "Mikol Modesti"

Claim this Profile
H
Hypoxia-Inducible Factor in Renal Cell Carcinoma: From Molecular Insights to Targeted Therapies.
Giandomenico Roviello, Irene De Gennaro, Ismaela Vascotto, Giulia Venturi, Alberto D'Angelo, Mikol Modesti

Genes (Basel)· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 Study.
Giuseppe Fotia, Calogero Saieva, Richard Lee-Ying, Anna Patrikidou, Pier Vitale Nuzzo, Mikol Modesti

Clin Genitourin Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer.
Bianca Calì, Martina Troiani, Silvia Bressan, Giuseppe Attanasio, Sara Merler, Mikol Modesti

Cancer Cell· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiandrogens as Therapies for COVID-19: A Systematic Review.
Massimiliano Cani, Samantha Epistolio, Giulia Dazio, Mikol Modesti, Giuseppe Salfi

Cancers (Basel)· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes of volume of disease on patients receiving enzalutamide abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
Pier Vitale Nuzzo, Francesco Ravera, Calogero Saieva, Elisa Zanardi, Giuseppe Fotia, Mikol Modesti

Ther Adv Med Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
Pier Vitale Nuzzo, Filippo Pederzoli, Calogero Saieva, Elisa Zanardi, Giuseppe Fotia, Mikol Modesti

J Transl Med· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis